Physician

Laura C. Dickerson, MD

According to 2025 Medicare claims, Laura Dickerson, MD (NPI: 1417031238) practices hematology/oncology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32605-4308.

Dickerson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,366 traditional Medicare patients, billed 371,198 HCPCS/CPT codes, and received $4,255,405 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,528 prescription claims across 341 beneficiaries totaling $3,013,987 in drug costs, led by Revlimid (Lenalidomide). DME data shows 37 claims. Open Payments data shows 24 records totaling $478. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,160,049 and ending at $3,013,987. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $20,757 to $12,926.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,408	361,111	$3,822,816
2016	1,433	416,090	$3,978,001
2017	1,807	312,623	$4,251,649
2018	2,003	312,231	$4,520,523
2019	2,049	386,067	$5,127,520
2020	1,979	388,370	$5,477,261
2021	1,972	294,132	$4,891,768
2022	1,484	256,578	$3,468,422
2023	1,264	289,719	$3,734,229
2024	1,366	371,198	$4,255,405

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	292	1,687	$1,160,049
2016	269	1,625	$1,764,343
2017	265	1,502	$2,084,834
2018	243	1,309	$2,182,531
2019	244	1,353	$2,493,872
2020	279	1,410	$1,906,599
2021	291	1,343	$1,665,984
2022	284	1,190	$1,594,921
2023	295	1,228	$1,817,086
2024	341	1,528	$3,013,987

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	105	440	$48,478
2016	83	293	$19,973
2017	57	149	$14,903
2018	44	98	$12,699
2019	23	87	$8,411
2020	27	81	$9,663
2021	31	34	$4,858
2022	16	19	$1,771
2023	31	34	$6,202
2024	31	37	$6,632

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	655	1,225	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	424	546	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	233	259	$13
36415	Insertion of needle into vein for collection of blood sample	1,168	2,742	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,185	3,067	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	46	1,190	$852,405
Verzenio	Abemaciclib	31	868	$475,971
Piqray	Alpelisib	15	420	$321,537
Imbruvica	Ibrutinib	19	532	$311,381
Lynparza	Olaparib	18	535	$132,823

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8030	Breast prosthesis, silicone or equal, without integral adhesive	N	11	11	$3,597
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	20	26	$3,035

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$478	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Laura C. Dickerson, MD?

Tedicare shows public-source Medicare data for Laura C. Dickerson, MD (NPI 1417031238), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Laura C. Dickerson, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Laura C. Dickerson, MD?

Laura C. Dickerson, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Laura C. Dickerson, MD have Open Payments data?

Laura C. Dickerson, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.